Video

Prognostic Tools for Early-Stage HER2+ Breast Cancer

A review of data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) examining the development and validation of prognostic tools for early stage HER2+ breast cancer.

Data from the following clinical trials are discussed:

  • First results from a phase 3 randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1–3 positive nodes, hormone receptor–positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPONDER) (Kalinsky K, et al. 2020 SABCS. Poster GS3-00).

  • Primary outcome results from the WSG-ADAPT HR+/HER2- trial: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0–3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy (Harbeck N., et al. 2020 SABCS. Poster GS4-04).

  • Continued efficacy of neratinib in patients with HER2-positive early stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (Holmes FA, et al. 2020 SABCS. Poster PD3-03).

  • Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early stage breast cancer (Ruiz-Borrego M, et al. 2020 SABCS. Poster PS13-20).

  • The DAPHNe trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer (Waks AG, et al. 2020 SABCS. Poster PD3-05).

  • Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: Analysis from the ALTTO (BIG 2-06) trial (Lambertini M, et al. 2020 SABCS. Poster PD3-04).

Related Videos
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
David Rimm, MD, PhD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School